ClinConnect ClinConnect Logo
Search / Trial NCT01414855

A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)

Launched by GENENTECH, INC. · Aug 10, 2011

Trial Information

Current as of July 23, 2025

Completed

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Adult patients, ≥18 years of age
  • Previously untreated cluster of differentiation antigen 20 (CD20)-positive diffuse large B-cell lymphoma
  • Ann Arbour Stage III/IV and bulky II (mass \>10 cm)
  • At least one bi-dimensionally measurable lesion defined as \>1.5 cm in its largest dimension by CT scan
  • Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
  • Left ventricular ejection fraction ≥50%
  • Adequate hematologic function
  • Exclusion Criteria:
  • Transformed lymphoma (follicular IIIB) if previously treated with chemotherapy or immunotherapy
  • Prior therapy for diffuse large B-cell lymphoma except for nodal biopsy or local irradiation
  • Central nervous system (CNS) lymphoma, primary mediastinal large cell lymphoma, primary cutaneous lymphoma, primary effusion lymphoma
  • Patients who received cytotoxic drugs or rituximab as part of their treatment for another condition (e.g. rheumatoid arthritis) or prior use of an anti-CD20 antibody
  • Chemotherapy or other investigational therapy within 28 days prior to the start of Cycle 1
  • Contraindication to any of the individual components of CHOP, including prior receipt of anthracyclines
  • History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
  • History of other malignancy, except for curatively treated basal or squamous cell carcinoma or melanoma of the skin or in situ carcinoma of the cervix, or malignancy treated with or without curative intent and in remission without treatment for ≥2 years prior to enrolment
  • Positive for hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or human T-cell leukemia virus (HTLV-1) infection
  • Pregnant or lactating women

About Genentech, Inc.

Genentech, Inc. is a leading biotechnology company and a member of the Roche Group, dedicated to transforming the lives of patients with serious medical conditions through innovative therapies. Established in 1976, Genentech is recognized for its pioneering research in biologics and for developing groundbreaking treatments in areas such as oncology, immunology, and neuroscience. With a commitment to scientific excellence and patient-centered care, the company leverages cutting-edge technology and collaborative partnerships to advance drug discovery and development. Genentech's robust pipeline and focus on personalized medicine underscore its mission to address unmet medical needs and improve health outcomes globally.

Locations

Hackensack, New Jersey, United States

New York, New York, United States

San Antonio, Texas, United States

Birmingham, Alabama, United States

Coeur D'alene, Idaho, United States

Worcester, Massachusetts, United States

Ames, Iowa, United States

Farmington, New Mexico, United States

Ann Arbor, Michigan, United States

Norwalk, Connecticut, United States

Yakima, Washington, United States

Las Vegas, Nevada, United States

Aurora, Colorado, United States

Houston, Texas, United States

Tyler, Texas, United States

Louisville, Kentucky, United States

Fort Myers, Florida, United States

Marietta, Georgia, United States

Charleston, South Carolina, United States

Spokane, Washington, United States

Encinitas, California, United States

Saint Petersburg, Florida, United States

Springfield, Oregon, United States

Houston, Texas, United States

Vancouver, Washington, United States

Missoula, Montana, United States

Roanoke, Virginia, United States

Denver, Colorado, United States

Chicago, Illinois, United States

Peoria, Illinois, United States

Basking Ridge, New Jersey, United States

Commack, New York, United States

Rockville Centre, New York, United States

Sleepy Hollow, New York, United States

High Point, North Carolina, United States

Nashville, Tennessee, United States

Fort Worth, Texas, United States

Green Bay, Wisconsin, United States

Patients applied

0 patients applied

Trial Officials

Clinical Trials

Study Director

Genentech, Inc.

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials